News

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.

Dr. Yeh discusses how Innovations in AI may improve access for patients in resource limited setting and improve detection of vision-threatening diseases.

The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.

A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.

A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration.

New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.

Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.

Brolucizumab every four weeks met efficacy end points versus aflibercept at end of MERLIN study, but with higher incidences of intraocular inflammation.

GATHER2 reports a 14.3% reduction in mean rate of growth in GA area over 12 months with avacincaptad pegol compared to sham.

The least squares mean change from baseline in BCVA at Week 8 was 6.7 letters for SB15 versus 6.6 letters for aflibercept.

The FDA granted a Priority Review to the leniolisib New Drug Application (NDA) indicated for individuals with activated phosphoinositide 3-kinase delta syndrome (APDS) 12 years and older.

A study finds delayed puberty, a comorbidity of epidermolysis bullosa, may affect skeletal health.

The FDA approved risankizumab for patients with Crohn's disease in June.

The research examined how anxiety and pre-bedtime behaviors that are often reported in primary care settings impact sleep health and discussed targeted interventions for effective treatment.

The FDA recently approved a drug treatment for prurigo nodularis, studied across over 60 clinical trials.

The investigators identified Osteoprotegerin in the serum of dupilumab treated patients, which could act as a predictor for clinical outcomes of dupilumab treatment.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

A discussion on the positive outcomes of acupuncture for Parkinson’s patients struggling with the effects of anxiety.

Key opinion leaders in the cardiometabolic space describe the importance of the introduction of SGLT2 inhibitors for heart failure treatment based on 2022 guidelines.

The study explores the relationship between the ascending arousal network, its alterations, and its connections with cortical networks in chronic insomnia disorder.

The treatment resulted in significant improvements in the Eczema Area and Severity Index (EASI) scores and patient-reported outcome measure scores.

The majority of patients treated with systemic therapies were treated with dupilumab, while 3.2% patients received a combination of systemic therapies.

The investigators found minor differences in the microbial community structure between the control group and the chronic HCV group.

A majority of individuals who received one of the various cannabinoid products experienced a significant improvement in sleep quality and duration.